|
|
|
01.12.25 - 14:03
|
ProQR to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET....
|
|
|
|
|
06.11.25 - 13:03
|
ProQR Announces Third Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the third quarter ended September 30, 2025, and provided a business update....
|
|
|
20.10.25 - 14:03
|
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR's Clinical Trial Application (CTA) for a Phase 1 study of AX-0810 in healthy volunteers. AX-0810 is the Company's lead investigational editing oligonucleotide (EON) targeting NTCP, which is being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia....
|
|
|
13.10.25 - 14:33
|
ProQR to Participate in Upcoming Investor Conferences in October 2025 (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences: ...
|
|
|
|
|
07.08.25 - 13:03
|
ProQR Announces Second Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the second quarter ended June 30, 2025, and provided a business update....
|
|
|
26.06.25 - 22:33
|
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases....
|
|
|
|
|
08.05.25 - 13:03
|
ProQR Announces First Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update....
|
|
|
02.05.25 - 14:03
|
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT....
|
|
|
14.04.25 - 13:03
|
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage....
|
|
|
|
|
13.03.25 - 12:03
|
ProQR Announces Year End 2024 Operating and Financial Results (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2024, and provided a business update....
|
|
|
12.12.24 - 13:12
|
ProQR expands partnership with RSRT to advance Rett Syndrome therapy (PBR)
|
|
|
The total funding is set to amount to $9.1m and the initial research grant of $1m was announced in January this year. The additional funding from RSRT will
The post ProQR expands partnership with RSRT to advance Rett Syndrome therapy appeared first on Pharmaceutical Business review....
|
|
|
10.12.24 - 14:06
|
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist (GlobeNewswire EN)
|
|
|
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
